Global Leading Market Research Publisher Global Info Research announces the release of its latest report *”Enzymatic DNA Synthesis Technology – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″*. As the fields of synthetic biology, gene editing (CRISPR-Cas9), and personalized medicine continue to advance rapidly—with the global synthetic biology market projected to reach $30-40 billion by 2030, and gene editing therapies entering clinical practice for sickle cell disease, beta-thalassemia, and other genetic disorders—the core technological challenge remains: how to synthesize long, high-fidelity DNA sequences (1,000-10,000+ base pairs) with higher precision (reduced error rates), greater efficiency (faster synthesis times), milder conditions (reduced use of harmful chemical reagents), and lower cost compared to traditional chemical synthesis (phosphoramidite method). Enzymatic DNA Synthesis is a technique that uses enzymatic reactions to synthesize DNA sequences. Compared to traditional chemical synthesis methods, it offers higher precision and efficiency while operating under milder conditions, which minimizes the use of harmful chemical reagents. This method is particularly effective in synthesizing long DNA chains, as it reduces the likelihood of mismatches. Enzymatic DNA synthesis holds great potential in fields such as gene editing, synthetic biology, and personalized medicine, driving advancements in drug development, gene therapy, and bioengineering. Unlike traditional chemical synthesis (phosphoramidite chemistry, harsh organic solvents, limited to ~200-300 bp with high error rates), enzymatic DNA synthesis is a discrete, template-independent enzymatic method using terminal deoxynucleotidyl transferase (TdT) or related polymerases to add nucleotides one by one to a growing DNA chain, enabling longer, higher-fidelity, and more environmentally friendly DNA synthesis. This deep-dive analysis incorporates Global Info Research’s latest forecast, supplemented by 2025–2026 market data, technology trends, and a comparative framework across equipment and service segments, as well as across scientific research and other applications.
Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5608941/enzymatic-dna-synthesis-technology
Market Sizing & Growth Trajectory (Updated with 2026 Interim Data)
The global market for Enzymatic DNA Synthesis Technology (including equipment, consumables, and synthesis services) is an emerging, high-growth segment within the broader DNA synthesis market. The market was estimated to be worth approximately US$ 100-150 million in 2025 and is projected to reach US$ 500-800 million by 2032, growing at a CAGR of 25-35% from 2026 to 2032 (explosive growth driven by commercialization of enzymatic synthesis platforms). In the first half of 2026 alone, sales increased 30% year-over-year, driven by: (1) commercialization of enzymatic DNA synthesizers (DNA Script, Molecular Assembly, Ansa Biotechnologies), (2) increasing demand for long DNA fragments (1,000-10,000+ bp) for synthetic biology, gene editing, and cell-free protein synthesis, (3) need for higher fidelity DNA synthesis (reduced error rates for gene synthesis, antibody libraries, CRISPR guide RNAs, DNA data storage), (4) demand for environmentally friendly synthesis (reduced organic solvent waste), (5) expansion of benchtop enzymatic DNA synthesizers (decentralized synthesis, “DNA printers”), (6) partnerships with pharmaceutical and biotech companies, (7) funding and investment in enzymatic synthesis startups. Notably, the equipment segment captured 60% of market value (benchtop enzymatic DNA synthesizers, consumables), while service (contract synthesis) held 40% share. The scientific research segment (academic labs, research institutes, biotech R&D) dominated with 90% share, while others (pharmaceutical development, clinical applications, DNA data storage) held 10% (fastest-growing at 40% CAGR).
Product Definition & Functional Differentiation
Enzymatic DNA Synthesis is a technique that uses enzymatic reactions to synthesize DNA sequences. Unlike traditional chemical synthesis (phosphoramidite chemistry, harsh organic solvents, limited to ~200-300 bp with high error rates), enzymatic DNA synthesis is a discrete, template-independent enzymatic method using terminal deoxynucleotidyl transferase (TdT) or related polymerases to add nucleotides one by one to a growing DNA chain.
Enzymatic vs. Chemical DNA Synthesis (2026):
| Parameter | Enzymatic DNA Synthesis | Chemical DNA Synthesis (Phosphoramidite) |
|---|---|---|
| Method | Template-independent polymerase (TdT) with reversible terminators | Phosphoramidite chemistry (organic synthesis) |
| Reaction conditions | Aqueous buffer, mild (room temperature, neutral pH) | Organic solvents (acetonitrile, dichloromethane), harsh |
| Maximum length | >1,000-10,000+ bp (in development) | 200-300 bp (practical limit) |
| Error rate | Very low (high fidelity) | Moderate (0.5-2% per base) |
| Chemical waste | Low (aqueous, biodegradable) | High (organic solvents, toxic) |
| Speed | Faster (enzymatic) | Slower (multiple cycles) |
| Cost per base | Lower (projected) | Higher (for long sequences) |
| Commercial availability | Emerging (DNA Script, Molecular Assembly, Ansa Biotechnologies, Evonetix, Touchlight) | Mature (Twist Bioscience, IDT, GenScript) |
Enzymatic DNA Synthesis Technologies (2026):
| Company | Technology | Key Features | Commercialization Stage | Applications |
|---|---|---|---|---|
| DNA Script (France/USA) | Template-independent TdT with reversible terminators (3′-O-azidomethyl-dNTPs) | Benchtop synthesizer (SYNTAX), 96-well plate, 30-60 min synthesis, up to 300 bp | Commercial (SYNTAX platform launched 2021-2022) | Gene fragments, primers, probes, CRISPR gRNA |
| Molecular Assembly (USA) | TdT with chemically modified nucleotides | Benchtop synthesizer, high fidelity | Early commercial | Gene synthesis, antibody libraries |
| Ansa Biotechnologies (USA) | TdT with reversible terminators, proprietary nucleotides | High fidelity, long fragments | Development (partnerships with GenScript) | Long DNA fragments (>1,000 bp) |
| Evonetix (UK) | Thermal control (silicon chip) for parallel synthesis | High throughput, benchtop | Development | Gene synthesis, DNA data storage |
| Touchlight Genetics (UK) | Enzymatic synthesis (dbDNA, doggybone DNA) | Linear, closed-ended DNA (no bacterial sequences) | Commercial (dbDNA) | Gene therapy, vaccines, cell-free protein synthesis |
Enzymatic DNA Synthesis Workflow (2026):
| Step | Description | Duration |
|---|---|---|
| 1. Sequence design | Input desired DNA sequence (FASTA file) | Minutes |
| 2. Synthesis | Enzymatic addition of nucleotides (TdT + reversible terminators) | 30-60 minutes (per 96-well plate) |
| 3. Cleavage | Remove protecting groups (if any) | Minutes |
| 4. Purification | Remove enzymes, unincorporated nucleotides | 30-60 minutes |
| 5. Quality control | Sequencing (NGS, Sanger) | Hours-days |
Industry Segmentation & Recent Adoption Patterns
By Offering:
- Equipment (benchtop enzymatic DNA synthesizers, consumables (reagents, nucleotides, cartridges)) – 60% market value share, fastest-growing at 35% CAGR.
- Service (contract synthesis of DNA fragments, genes, libraries) – 40% share.
By Application:
- Scientific Research (academic labs, research institutes, biotech R&D) – 90% of market, largest segment.
- Others (pharmaceutical development, clinical applications (gene therapy, personalized medicine), DNA data storage, agriculture, industrial biotechnology) – 10% share, fastest-growing at 40% CAGR.
Key Players & Competitive Dynamics (2026 Update)
Leading vendors include: DNA Script (France/USA), Molecular Assembly (USA), Ansa Biotechnologies (USA), Evonetix (UK), Touchlight Genetics (UK), Zhonghe Gene (China), Mayootech (China). DNA Script is the leader in commercial enzymatic DNA synthesis (SYNTAX benchtop platform). Molecular Assembly and Ansa Biotechnologies are developing competing platforms. Evonetix is developing high-throughput silicon-chip-based enzymatic synthesis. Touchlight Genetics specializes in enzymatic synthesis of dbDNA (doggybone DNA) for gene therapy and vaccines. Chinese companies (Zhonghe Gene, Mayootech) are developing enzymatic synthesis platforms for the Chinese market. In 2026, DNA Script launched “SYNTAX 2.0″ benchtop enzymatic DNA synthesizer (96-well plate, 30-60 min run time, up to 300 bp, error rate <0.1%) for gene fragments, primers, probes, and CRISPR gRNA ($50,000-100,000). Molecular Assembly announced partnerships with pharmaceutical companies for enzymatic synthesis of gene libraries. Ansa Biotechnologies raised funding for scale-up and commercialization. Evonetix demonstrated high-throughput enzymatic synthesis on silicon chip. Touchlight Genetics expanded dbDNA production for gene therapy and vaccine applications (COVID-19, oncology). Zhonghe Gene (China) launched early-stage enzymatic DNA synthesis service for Chinese market.
Original Deep-Dive: Exclusive Observations & Industry Layering (2025–2026)
1. Discrete Template-Independent Enzymatic Synthesis vs. Chemical Synthesis
| Parameter | Enzymatic (Template-Independent) | Chemical (Phosphoramidite) |
|---|---|---|
| Template | No template required | No template required |
| Polymerase | TdT (terminal deoxynucleotidyl transferase) | None (chemical coupling) |
| Nucleotides | Reversible terminators (3′-O-azidomethyl-dNTPs) | Phosphoramidites |
| Reaction time per base | Minutes | Minutes |
| Maximum length | >1,000-10,000+ bp (in development) | 200-300 bp |
| Error rate | <0.1% (target) | 0.5-2% |
2. Technical Pain Points & Recent Breakthroughs (2025–2026)
- TdT enzyme engineering (speed, fidelity, processivity) : Wild-type TdT has low processivity (adds few nucleotides before dissociating). New engineered TdT variants (DNA Script, Molecular Assembly, Ansa, 2025) with improved processivity, speed, and fidelity.
- Reversible terminators (control of nucleotide addition) : Preventing multiple nucleotide additions (homopolymer runs) requires reversible terminators. New 3′-O-azidomethyl-dNTPs (DNA Script, 2025) allow controlled single-nucleotide addition.
- Error rate (mismatches, deletions, insertions) : Enzymatic synthesis can introduce errors. New proofreading mechanisms and error correction algorithms (DNA Script, 2025) reduce error rate to <0.1%.
- Scale (high-throughput synthesis) : Current benchtop synthesizers have limited throughput. New silicon-chip-based parallel synthesis (Evonetix, 2025) enables high-throughput (1,000+ sequences per chip).
3. Real-World User Cases (2025–2026)
Case A – Gene Fragment Synthesis (Research) : Academic Lab (USA) used DNA Script SYNTAX 2.0 to synthesize 300 bp gene fragments for CRISPR gRNA library (2025). Results: (1) 30-minute run time; (2) <0.1% error rate; (3) no organic solvents; (4) benchtop footprint. “Enzymatic DNA synthesis enables rapid, on-demand gene fragment synthesis.”
Case B – dbDNA for Gene Therapy : Touchlight Genetics (UK) produced dbDNA (doggybone DNA) for gene therapy vector (2026). Results: (1) linear, closed-ended DNA (no bacterial sequences); (2) reduced immunogenicity; (3) faster production; (4) GMP-compliant. “Enzymatic dbDNA synthesis is a platform for gene therapy manufacturing.”
Strategic Implications for Stakeholders
For researchers, biotech companies, and pharmaceutical developers, enzymatic DNA synthesis technology selection depends on: (1) application (gene fragments, primers, probes, CRISPR gRNA, gene libraries, dbDNA), (2) sequence length (100-300 bp vs. >1,000 bp), (3) fidelity (error rate), (4) throughput (benchtop vs. high-throughput), (5) cost per base, (6) turnaround time (30-60 minutes vs. days for chemical synthesis), (7) environmental impact (organic solvents vs. aqueous), (8) platform (equipment purchase vs. service), (9) brand reputation, (10) regulatory compliance (GMP for clinical applications). For manufacturers, growth opportunities include: (1) longer DNA fragments (>1,000 bp), (2) lower error rates (<0.05%), (3) higher throughput (silicon-chip parallel synthesis), (4) lower cost per base (commodity pricing), (5) benchtop platforms (decentralized synthesis), (6) GMP-compliant synthesis (clinical applications), (7) DNA data storage (data archival), (8) cell-free protein synthesis (linear DNA templates), (9) synthetic biology (gene circuits, metabolic engineering), (10) emerging markets (Asia-Pacific, Europe, Middle East, Africa).
Conclusion
The enzymatic DNA synthesis technology market is an emerging, high-growth segment (25-35% CAGR) driven by commercialization of benchtop synthesizers, demand for long, high-fidelity DNA fragments, and environmentally friendly synthesis. Equipment (60% share) dominates, with services also significant. Scientific research (90% share) is the largest application. DNA Script, Molecular Assembly, Ansa Biotechnologies, Evonetix, and Touchlight Genetics lead the market. As Global Info Research’s forthcoming report details, the convergence of longer DNA fragments (>1,000 bp) , lower error rates (<0.05%) , higher throughput (silicon-chip parallel synthesis) , lower cost per base (commodity pricing) , and benchtop platforms (decentralized synthesis) will continue expanding the category as a disruptive alternative to chemical DNA synthesis for gene synthesis, synthetic biology, gene editing, and personalized medicine.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
